Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study

Athyros, Vasilios G.; Mikhailidis, Dimitri P.; Liberopoulos, Evangelos N.; Kakafika, Anna I.; Karagiannis, Asterios; Papageorgiou, Athanasios A.; Τζιόμαλος, Κωνσταντίνος; Ganotakis, Emmanuel S.; Elisaf, Moses

doi:10.1093/ndt/gfl538

Cited by 172 publications

(120 citation statements)

References 37 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…These results come in agreement with other studies demonstrating that multifactorial treatment, including statin therapy, may have a favourable impact on liver and kidney function. [28,29] Nevertheless, the most potent therapies were not preferred in our study. High-dose statin treatment was not used, while only 20% of the subjects were receiving combination treatment of statin + ezetimibe.…”

Section: Strategies Confronting Poor Multi-factorial Target Attainmentmentioning

confidence: 82%

Attainment of multifactorial treatment targets among elderly in a lipid clinic

et al. 2015

Self Cite

View full text Add to dashboard Cite

Section: Strategies Confronting Poor Multi-factorial Target Attainmentmentioning

confidence: 82%

Attainment of multifactorial treatment targets among elderly in a lipid clinic

et al. 2015

Self Cite

View full text Add to dashboard Cite

“…In support of a beneficial role for statins in ameliorating the progression of diabetic nephropathy, several clinical studies have reported findings of a preserved glomerular filtration rate and diminished urine albumin excretion in diabetic patients with proteinuria treated with statins (18,20,24,45,46). However, the molecular mechanism(s) responsible for the renoprotective effects of statins has been the subject of much debate.…”

Section: Discussionmentioning

confidence: 99%

Targeting of RhoA/ROCK Signaling Ameliorates Progression of Diabetic Nephropathy Independent of Glucose Control

Kolavennu

Zeng²,

Peng³

et al. 2008

Diabetes

186

167

View full text Add to dashboard Cite

OBJECTIVE-RhoA, a small GTPase protein, and its immediate downstream target, Rho kinase (ROCK), control a wide variety of signal transduction pathways. Recent studies have shown that fasudil, a selective ROCK inhibitor, may play a pivotal role in a number of pathological conditions, ranging from cardiovascular diseases to pulmonary hypertension and erectile dysfunction. Considerable evidence suggests that some of the beneficial effects of statins may also stem from their modulatory effects on RhoA/ROCK signaling. In the current study, we hypothesized that pharmacological blockade of the RhoA/ROCK pathway with either fasudil or simvastatin would ameliorate progression of diabetic nephropathy. RESULTS-The kidney cortices of untreated db/db mice displayed increased ROCK activity compared with db/m mice. The fasudil-treated mice exhibited a significant reduction in ROCK activity, albuminuria, glomerular collagen IV accumulation, and urinary collagen IV excretion compared with untreated db/db mice. Interestingly, blood glucose was unaffected by fasudil administration. Treatment with simvastatin significantly attenuated RhoA activation in the kidney cortices of db/db mice and resulted in a significant reduction of albuminuria and mesangial matrix expansion. RESEARCH DESIGN AND METHODS-InCONCLUSIONS-Based on these results, we propose that RhoA/ROCK blockade constitutes a novel approach to the treatment of diabetic nephropathy. Our data also suggest a critical role for RhoA/ROCK activation in the pathogenesis of diabetic nephropathy. Diabetes 57:714-723, 2008 T he Rho family of small GTPases are 20-to 40-kDa monomeric G proteins that regulate a number of cell functions, including cytoskeletal reorganization, cell motility, and gene expression (1). They cycle between two conformational states: an active GTPbound state and an inactive GDP-bound state (2). One of the best recognized members of the Rho GTPase family is RhoA. Rho kinase (ROCK), a downstream effector of RhoA, is a serine/threonine kinase of ϳ160 kDa that exists in two isoforms in mammals: ROCK1 and ROCK2 (3). ROCK is comprised of an amino-terminal kinase domain, followed by a coiled-coil region that contains the -binding domain. The carboxy-terminal consists of a plexstrinhomology domain, which contains an internal cysteinerich domain. ROCK1 and ROCK2 are highly homologous, sharing an identity of 65% in their overall amino acid sequences and 92% in their kinase domains.The RhoA/ROCK pathway has recently received considerable attention for its involvement in a wide variety of pathological states ranging from cardiovascular disease and pulmonary hypertension to Alzheimer's disease and glaucoma (4 -7). A growing body of evidence also suggests that the RhoA/ROCK pathway may have renomodulatory effects. Indeed, several recent studies have proposed that RhoA/ROCK may play an important role in renal fibrosis by enhancing signaling pathways involving transforming growth factor-␤, angiotensin II, and nuclear factor-B (8 -10). Furthermore, since the discovery of fasudi...

show abstract

“…Multifactorial treatment has several beneficial effects on both CVD and renal function, especially in high-risk patients such as those with MetS 36 and CKD 4,5 . Of note, statins were also shown to reduce SUA levels 37,38 . Antihypertensive treatment and especially drugs that block RAAS (i.e., converting enzyme inhibitors, angiotensin and aldosterone receptor antagonists) exert beneficial cardiovascular and renal effects 39 ; improvements in proteinuria as well as prevention of CKD progression, CVD morbidity and mortality have been reported in relation to such antihypertensive therapy [40][41][42] .…”

Section: I a L D I S T R I B U T I O N U N A U T H O R I Z E D U S mentioning

confidence: 99%

Multifactorial treatment for improvement of renal function and cardiovascular risk: an ATTEMPT for patients with metabolic syndrome and chronic kidney disease

Katsiki

Elisaf

2011

Current Medical Research and Opinion

View full text Add to dashboard Cite

Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study

Abstract: Among CHD patients, those with MetS benefited more from statin treatment than those without MetS. This benefit could be partially attributed to favourable changes in e-GFR and SUA levels probably induced by statin treatment.

Cited by 172 publications

References 37 publications

Attainment of multifactorial treatment targets among elderly in a lipid clinic

Attainment of multifactorial treatment targets among elderly in a lipid clinic

Targeting of RhoA/ROCK Signaling Ameliorates Progression of Diabetic Nephropathy Independent of Glucose Control

Multifactorial treatment for improvement of renal function and cardiovascular risk: an ATTEMPT for patients with metabolic syndrome and chronic kidney disease

Contact Info

Product

Resources

About